Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Study Identifier
190342-019T
CT.gov Identifier
NCT00652106
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
  • Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
  • Brimonidine 0.2% ophthalmic solution
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Diagnosis of ocular hypertension or glaucoma * Patient requires IOP-lowering therapy in both eyes
    Exclusion Criteria:
    * Uncontrolled medical conditions * Contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy

    Protocol Summary

    This study evaluates the safety and efficacy of brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution compared with concurrent brimonidine 0.2% and timolol ophthalmic solutions

    Study Locations

    Location
    Status
    Location
    El Paso, Texas, United States
    Status
    Not applicable